[MTMD] MICROTEK MED HLDG › 3.57 +0.08 ( +2.29%)
stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G
Microtek Medical Holdings, Inc., though its subsidiaries, engages in the manufacture and supply of product for patient care, occupational safety, and management of infectious and hazardous waste for the healthcare market primarily in the United States and United Kingdom. It offers infection control products, fluid control products, safety products, and other products to healthcare professionals for use in environments, such as operating rooms and ambulatory surgical centers. The company’s primary products consist of disposable equipment drapes and specialty patient drapes. Microtek’s line of equipment drapes consists of drapes for use in draping operating room equipment during surgical procedures. Its patient drapes comprise both nonwoven and plastic patient drapes. The company’s nonwoven patient drapes include specialty patient drapes with fluid collection pouches, incise, and procedure-specific designs. Microtek also offers a line of products and supplies used to clean a procedural room; encapsulation products for the management of infectious and hazardous waste, including absorbent powders, which convert infectious liquid waste to a solid form; venodyne pneumatic pumps and disposable compression sleeves used in reducing deep vein thrombosis, decanters used for sterile transfer of fluids, disposable pouches or fluid-control products that are attached to patient drapes to collect fluids; and wound evacuation products. In addition, the company provides dip-molded medical devices, primarily ultrasound probe covers, other equipment covers, cardiac thoracic drain systems, gynecological devices, and wound care products.
[ISV] INSITE VISION INC › 0.71 +0.05 ( +7.58%)
stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G
InSite Vision Incorporated, an ophthalmic product development company, develops genetically-based technology for the diagnosis, prognosis, and management of glaucoma, ocular infections, and retinal diseases. The company also focuses on ophthalmic pharmaceutical products based on its DuraSite eyedrop-based drug delivery technology. Its principal product, AzaSite, targets infections of the eye.
|
